Antibody-mediated rejection (AMR) has emerged as an important cause of lung graft failure.
The lung allograft functions as a secondary lymphoid organ
While the prevailing view in solid organ transplant and other areas of immunology is that adaptive immune responses are initiated and regulated in secondary lymphoid organs, such as lymph nodes and spleen, the lung has its own secondary lymphoid tissue in the form of bronchus-associated lymphoid tissue (BALT). Antibody-mediated rejection (AMR) has become an increasingly recognized contributor to acute and chronic lung allograft dysfunction in lung transplant recipients, leading to a recent consensus definition from the International Society for Heart and Lung Transplantation (ISHLT) (1). In the current study by Li et Figure  1 ). The authors show that when allografts from tolerant mice are transplanted into a second recipient, depleting these allograft regulatory T cells consistently results in AMR. Therefore, the regulation of allogeneic humoral responses continues to occur within the lung allograft itself. This finding parallels that of a previous report by the same group demonstrating that, very shortly after transplantation, priming of alloreactive T cells occurs within the lung allograft as well (3) . Understanding these unique aspects of immune activation and regulation of alloimmune responses in lung transplantation is critically important in order to better adapt current immunosuppressive strategies that are broadly applied across multiple organs to an allograft that is truly, itself, a secondary lymphoid organ.
Pulmonary AMR is characterized pathologically by acute lung injury
As AMR in lung transplant has only recently been fully recognized as an important cause of lung allograft dysfunction, the description and definition of underlying pathology are also recent and evolving. Here, the authors describe lung allograft pathology in mouse recipients with antibodies directed against alloantigen known to be the cause of allograft injury. These lung allografts are characterized by pathology completely consistent with acute lung injury (ALI) and diffuse alveolar damage/alveolar edema with hyaline membrane formation, along with complement deposition and airway epithelial injury. Interestingly, ALI pathology has been shown to be a common manifestation of AMR in lung allograft recipients, making this AMR mouse model important in a pathologic correlate context (4 
Retransplantation of Foxp3
+ -depleted lung allografts: model of pulmonary AMR One of the many challenges in uncovering cellular and molecular mechanisms contributing to allograft dysfunction in lung transplantation has been the lack of animal models that adequately mimic the human scenario. For example, achieving a reproducible animal model to study obliterative bronchiolitis, a manifestation of chronic allograft rejection in lung transplant recipients, remains challenging, though some progress has recently been made (6). While the experiments required to generate this mouse model of pulmonary AMR are labor intensive and require significant expertise to conduct, the model itself enables mechanistic studies that will facilitate further understanding of how better to prevent AMR in lung transplantation as well as how to treat it once it occurs. Impor- + T cells may be important in the prevention and resolution of ALI from any cause in lung transplantation.
